Sanofi (SNY)
(Delayed Data from NSDQ)
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:20 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:20 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Court Ruling Topples Trump Order, No Price Display in TV Ads
by Zacks Equity Research
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs
by Kinjel Shah
Pfizer (PFE) provides several regulatory/pipeline updates. CHMP gives nod to several drugs.
Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III
by Zacks Equity Research
Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.
Roche's Flu Medicine Xofluza Meets Goal in Study on Kids
by Zacks Equity Research
Roche's (RHHBY) new flu medicine, Xofluza is well tolerated in a study in children aged between one to 12 years. It is also comparable to Roche's older flu medicine, Tamiflu,
Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance
by Zacks Equity Research
Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.
Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis
by Zacks Equity Research
Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.
Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer
by Zacks Equity Research
Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.
Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation
by Zacks Equity Research
Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.
Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu
by Zacks Equity Research
Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.
FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review
by Zacks Equity Research
The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.
Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.
Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
by Zacks Equity Research
Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
by Kinjel Shah
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens
Alphabet's Healthcare Push Gains Steam: Others Brace Up
by Shilpa Mete
Alphabet's (GOOGL) Google's partnership with Sanofi provides it a competitive edge in the healthcare sector.
Sanofi Partners Google to Build Healthcare Innovation Lab
by Zacks Equity Research
Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.
Protalix (PLX) Completes Enrollment in Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
by Zacks Equity Research
Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
by Kinjel Shah
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Lilly Announces Tradjenta Cardiovascular Outcome Study Data
by Zacks Equity Research
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Sanofi (SNY) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Sanofi (SNY) shares rose nearly 6% in the last trading session, amid huge volumes.
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
by Kinjel Shah
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Novartis Appoints New Pharma Unit Head, Gives Other Updates
by Zacks Equity Research
Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
by Kinjel Shah
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.